OCTA

OCTA
Name	Optical Coherence Tomography Angiography
Caption	Optical coherence tomography angiography scan
Invented	Early 2010s
Inventor	Multiple research groups and companies
Field	Ophthalmology, Optometry, Biomedical imaging

OCTA

Optical coherence tomography angiography is a noninvasive imaging modality that provides depth-resolved visualization of microvascular networks in the retina and choroid. Developed from interferometric optical techniques, OCTA enables clinicians and researchers to assess perfusion without intravenous contrast, complementing established examinations in ophthalmic centers, academic hospitals, and industry laboratories. The technique has rapidly influenced practice patterns in clinics associated with Moorfields Eye Hospital, Bascom Palmer Eye Institute, Massachusetts General Hospital, Johns Hopkins Hospital, and multinational companies like Zeiss, Optovue, and Heidelberg Engineering.

Introduction

OCTA integrates principles from technologies pioneered at institutions such as MIT, Stanford University, National Institutes of Health, University of California, Berkeley, and University College London to render motion contrast of blood flow within ocular tissues. Early translational work involved collaborations among investigators from Harvard Medical School, University of Washington School of Medicine, Duke University School of Medicine, and industry partners including Topcon and Canon Medical Systems. Adoption accelerated after presentations at meetings hosted by Association for Research in Vision and Ophthalmology, American Academy of Ophthalmology, and European Society of Retina Specialists.

Technology and Principles

OCTA is based on low-coherence interferometry, leveraging swept-source and spectral-domain platforms developed in labs at Optical Society of America-associated conferences and institutions such as Rochester Institute of Technology. The method detects temporal decorrelation between sequential B-scans to map erythrocyte motion, using algorithms like split-spectrum amplitude-decorrelation, optical microangiography, and complex differential approaches introduced in publications from NIH-funded groups. Hardware advances from companies including Nidek, Canon, and Carl Zeiss Meditec improved scanning speeds and signal-to-noise ratios, while software contributions from teams at University of Miami Miller School of Medicine and Wilmer Eye Institute enhanced segmentation and projection-resolved visualization.

Clinical Applications

Clinically, OCTA informs management of retinal vascular diseases seen at centers such as Wills Eye Hospital and Cole Eye Institute. It assists diagnosis and monitoring of neovascular age-related macular degeneration commonly treated with agents developed by Genentech, Regeneron, and Novartis. Diabetic retinopathy staging, pivotal in trials conducted by groups affiliated with Joslin Diabetes Center and Diabetes Control and Complications Trial investigators, benefits from OCTA-derived capillary nonperfusion metrics. OCTA also evaluates retinal vein occlusion cases managed by clinicians at Moorfields Eye Hospital and aids glaucoma assessment pursued at Bascom Palmer Eye Institute and Massachusetts Eye and Ear Infirmary.

Interpretation and Image Analysis

Interpretation involves correlating en face and cross-sectional angiograms with structural OCT and clinical examination performed in settings like Cleveland Clinic Cole Eye Institute and academic departments at University of California, Los Angeles. Automated vessel density, foveal avascular zone metrics, and fractal analysis developed in partnerships between Imperial College London and engineering groups at University of Toronto are used for quantitative research and multicenter trials coordinated by organizations such as World Health Organization-affiliated registries. Machine learning models from collaborations with Google Health, DeepMind, and university research labs have been proposed to assist in classification and prognosis.

Limitations and Artifacts

OCTA interpretation must account for motion artifacts, projection artifacts, and segmentation errors documented in multicenter evaluations led by investigators at Brigham and Women's Hospital and Mayo Clinic. Media opacities encountered in patients referred from community clinics and tertiary centers can degrade signal, while slow flow below the detection threshold may be misinterpreted as nonperfusion—a concern raised in consensus statements from professional societies including American Academy of Ophthalmology and European Society of Retina Specialists. Reproducibility challenges in multicenter trials require standardization efforts similar to those by Food and Drug Administration working groups and instrument-specific calibration protocols advocated by manufacturers like Carl Zeiss Meditec.

Comparative Imaging Modalities

OCTA complements dye-based angiography techniques such as fluorescein angiography and indocyanine green angiography historically employed at institutions like University of Iowa Hospitals and Clinics and King's College Hospital. Compared with adaptive optics imaging developed at University of Rochester and wide-field modalities from Optos, OCTA provides depth-resolved microvascular maps without systemic injection risks documented in pharmacovigilance reports reviewed by European Medicines Agency. Hybrid approaches combining OCTA with ultra-widefield fluorescein studies are increasingly used in multicenter clinical trials sponsored by consortia including National Eye Institute-funded networks.

History and Development

The conceptual roots of OCTA trace to interferometry and optical coherence tomography milestones at MIT, Stanford University, and Massachusetts Institute of Technology laboratories, with seminal OCT work by groups associated with Harvard Medical School and Massachusetts General Hospital. The transition to angiographic applications accelerated with algorithmic innovations from teams at University of California, Davis and Shanghai Jiao Tong University and commercial translation by Optovue and Zeiss in the early 2010s. Subsequent iterations incorporated contributions from global research centers including University of Sydney, Kyoto University, Charité – Universitätsmedizin Berlin, and Peking University to become a routine tool across academic, private, and industry imaging portfolios.

Category:Ophthalmic imaging